Mixed Chimeric Transplantation for Primary Amyloidosis

Not Applicable

Withdrawn

• Conditions: Amyloidosis

• Registration Number: NCT00186095
• Lead Sponsor: Stanford University

Brief Summary

To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-12
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-16
• Study Completion: 2006-09
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-16
• Last Update Posted: 2022-06-23

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• primary amyloidosis
• adequate organ function
• matched sibling donor

Exclusion Criteria

• evidence of multiple myeloma
• HIV positive

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.

Secondary Outcome Measures

Name	Time	Method
Toxicity of therapy
Changes in marrow and serum abnormalities
Improvement in end-organ function.